Pharmacologic treatment of repetitive behaviors in autism spectrum disorders: Evidence of publication bias

Pediatrics

Volumn 129, Issue 5, 2012, Pages

  Carrasco, Melisa ^a   Volkmar, Fred R ^b   Bloch, Michael H ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressive agents; Autism; Meta analysis; Pervasive child development disorders; Publication bias

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PLACEBO; SERTRALINE;

ADOLESCENT; AGE; ARTICLE; AUTISM; CHILD; COMPULSION; CONFIDENCE INTERVAL; DRUG EFFICACY; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; PUBLICATION; PUBLISHING; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; STEREOTYPED BEHAVIOR; STEREOTYPIC MOVEMENT DISORDER;

EID: 84860580549     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-3285     Document Type: Article

References (59)

1. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res. 2009;65(6):591-598
2. Lord C. Autism spectrum disorders. Society for Research in Child Development: Social Policy Report. 2010;24(2):1-27
3. Kim YS, Leventhal BL, Koh YJ, et al. Prevalence of autism spectrum disorders in a total population sample. Am J Psychiatry. 2011;168(9):904-912
4. Lord C. Epidemiology: How common is autism? Nature. 2011;474(7350):166- 168
5. Rapin I. The autistic-spectrum disorders. N Engl J Med. 2002;347(5):302-303
6. Richler J, Bishop SL, Kleinke JR, Lord C. Restricted and repetitive behaviors in young children with autism spectrum disorders. J Autism Dev Disord. 2007;37(1):73-85 (Pubitemid 46197896)
7. Richler J, Huerta M, Bishop SL, Lord C. Developmental trajectories of restricted and repetitive behaviors and interests in children with autism spectrum disorders. Dev Psychopathol. 2010;22(1):55-69
8. Dunlap G, Dyer K, Koegel RL. Autistic self-stimulation and intertrial interval duration. Am J Ment Defic. 1983;88(2):194-202 (Pubitemid 13006544)
9. Gabriels RL, Cuccaro ML, Hill DE, Ivers BJ, Goldson E. Repetitive behaviors in autism: relationships with associated clinical features. Res Dev Disabil. 2005;26(2):169-181 (Pubitemid 39601457)
10. Zandt F, Prior M, Kyrios M. Similarities and differences between children and adolescents with autism spectrum disorder and those with obsessive compulsive disorder: executive functioning and repetitive behaviour. Autism. 2009;13(1):43-57
11. Zandt F, Prior M, Kyrios M. Repetitive behaviour in children with high functioning autism and obsessive compulsive disorder. J Autism Dev Disord. 2007;37(2):251-259
12. Bodfish JW, Symons FJ, Parker DE, Lewis MH. Varieties of repetitive behavior in autism: comparisons to mental retardation. J Autism Dev Disord. 2000;30(3):237-243
13. McDougle CJ, Kresch LE, Goodman WK, et al. A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry. 1995;152(5):772-777
14. Gross-Isseroff R, Hermesh H, Weizman A. Obsessive compulsive behaviour in autism - towards an autistic-obsessive compulsive syndrome? World J Biol Psychiatry. 2001;2(4):193-197
15. Hollander E, King A, Delaney K, Smith CJ, Silverman JM. Obsessive-compulsive behaviors in parents of multiplex autism families. Psychiatry Res. 2003;117(1):11-16 (Pubitemid 36173772)
16. Micali N, Chakrabarti S, Fombonne E. The broad autism phenotype: findings from an epidemiological survey. Autism. 2004;8(1):21-37 (Pubitemid 38239620)
17. Hollander E, Kim S, Braun A, Simeon D, Zohar J. Cross-cutting issues and future directions for the OCD spectrum. Psychiatry Res. 2009;170(1):3-6
18. Jacob S, Landeros-Weisenberger A, Leckman JF. Autism spectrum and obsessivecompulsive disorders: OC behaviors, phenotypes and genetics. Autism Res. 2009;2(6):293-311
19. Lewis MH. Brief report: psychopharmacology of autism spectrum disorders. J Autism Dev Disord. 1996;26(2):231-235 (Pubitemid 26140734)
20. Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2008;(1):CD001765
21. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318(26):1728-1733
22. Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry. 2010;15(8):850-855
23. Ipser JC, Stein DJ, Hawkridge S, Hoppe L. Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev. 2009;(3):CD005170
24. Williams K, Wheeler DM, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2010;(8):CD004677
25. Mandell DS, Morales KH, Marcus SC, Stahmer AC, Doshi J, Polsky DE. Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics. 2008;121(3). Available at: www.pediatrics.org/ cgi/content/full/121/3/e441
26. Oswald DP, Sonenklar NA. Medication use among children with autism spectrum disorders. J Child Adolesc Psychopharmacol. 2007;17(3):348-355 (Pubitemid 47067958)
27. Rosenberg RE, Mandell DS, Farmer JE, Law JK, Marvin AR, Law PA. Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007-2008. J Autism Dev Disord. 2010;40(3):342-351
28. Scahill L, McDougle CJ, Williams SK, et al Research Units on Pediatric Psychopharmacology Autism Network. Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 2006;45(9):1114-1123 (Pubitemid 44343067)
29. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006-1011 (Pubitemid 19278229)
30. Scahill L, Riddle MA, McSwiggin-Hardin M, et al. Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry. 1997;36(6):844-852 (Pubitemid 27250450)
31. Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89(5):485-491 (Pubitemid 15104762)
32. Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials. 1995;16(1):62-73
33. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. Chichester, UK: John Wiley & Sons, Ltd; 2009
34. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634 (Pubitemid 27387172)
35. Dichter G. Functional MRI evaluation of the effect of citalopram in autism spectrum disorders. Available at: http://clinicaltrials.gov/ct2/show/ NCT00609531. Accessed April 23, 2011
36. Deeks J, Higgins J, Altman D. Cochrane Reviewers' Handbook 4.2.1. Chichester, UK: John Wiley & Sons, Ltd; 2003
37. Anagnostou E, Esposito K, Soorya L, Chaplin W, Wasserman S, Hollander E. Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder. J Clin Psychopharmacol. 2006;26(4):444-446 (Pubitemid 44187659)
38. Dinca O, Paul M, Spencer NJ. Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders. J Psychopharmacol. 2005;19(5):521-532 (Pubitemid 41392307)
39. Sugie Y, Sugie H, Fukuda T, et al. Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism. J Autism Dev Disord. 2005;35(3):377-385 (Pubitemid 41125975)
40. Mathai J, Bourne A, Cranswick N. Lessons learnt in conducting a clinical drug trial in children with Asperger Syndrome. Australas Psychiatry. 2005;13(2):173-175 (Pubitemid 40936478)
41. Fukuda T, Sugie H, Ito M, Sugie Y. Clinical evaluation of treatment with fluvoxamine, a selective serotonin reuptake inhibitor in children with autistic disorder [article in Japanese]. No To Hattatsu. 2001;33(4):314-318 (Pubitemid 32634472)
42. Neuropharm. Study of fluoxetine in autism (SOFIA). Available at: http://clinicaltrials.gov/ct2/show/NCT00515320. Accessed April 23, 2011
43. FDA Office of Orphan Products Development. Study of fluoxetine in adults with autistic disorder. Available from: http://clinicaltrials.gov/ct2/show/ NCT00027404. Accessed April 23, 2011
44. The Hospital for Sick Children. Fluvoxamine and sertraline in childhood autism - does SSRI therapy improve behaviour and/or mood? Available at: http://clinicaltrials.gov/ct2/show/NCT00655174. Accessed April 23, 2011
45. National Institute of Mental Health (NIMH). Effectiveness of early intervention with fluoxetine in enhancing developmental processes in children with autism (STAART study 2). Available at: http://clinicaltrials.gov/ct2/show/ NCT00183339. Accessed April 23, 2011
46. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry. 1993;50(6):441-447 (Pubitemid 23169937)
47. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry. 1996;53(11):1001-1008 (Pubitemid 26384669)
48. Remington G, Sloman L, Konstantareas M, Parker K, Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol. 2001;21(4):440-444 (Pubitemid 32673034)
49. Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology. 2005;30(3):582-589 (Pubitemid 40271160)
50. King BH, Hollander E, Sikich L, et al STAART Psychopharmacology Network. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry. 2009;66(6):583-590
51. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455-463 (Pubitemid 30422636)
52. McDougle CJ, Kresch LE, Posey DJ. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord. 2000;30(5):427-435
53. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ. 1999;319(7211):670-674 (Pubitemid 29423954)
54. Leekam SR, Prior MR, Uljarevic M. Restricted and repetitive behaviors in autism spectrum disorders: a review of research in the last decade. Psychol Bull. 2011;137(4):562-593
55. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-260
56. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004;363(9418):1341-1345
57. Reyes MM, Panza KE, Martin A, Bloch MH. Time-lag bias in trials of pediatric antidepressants: a systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry. 2011;50(1):63-72
58. Kolevzon A, Mathewson KA, Hollander E. Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability. J Clin Psychiatry. 2006;67(3):407-414
59. Law MR, Kawasumi Y, Morgan SG. Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov. Health Aff (Millwood). 2011;30(12):2338-2345